TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05610865

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control; Standard-of-care management
Description: Patients will undergo conventional wound care management.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Only PRP injection
Description: Only PRP injected / cm2 intradermally at the border zone \& inside of wound surface bed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP + SVF injection
Description: Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP + ASCs injection
Description: Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
Study: NCT03240692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated theta-burst stimulation treatment
Description: All participants will receive intermittent theta-burst stimulation (iTBS) to the left dorsal lateral prefrontal cortex (L-DLPFC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered to L-DLPFC using the Magventure Magpro X100 and/or the NextStim TMS system.
Study: NCT02640807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) \>2.5 or platelet count \< 35,000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) \>2.5 or platelet count \< 35,000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
Study: NCT00515112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AndroGel
Description: Androgel 1%, 10g daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01825785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT02910336

Intervention type: OTHER
Intervention: Quantitative Sensory Testing
Description: sensory testing profile

Intervention type: OTHER
Intervention: Quantitative Sensory Testing
Description: sensory testing profile
Study: NCT03759132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different chronic neurological conditions, including Parkinson's disease.
Study: NCT03303690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle Spacer (AS)
Description: All included patients will be treated by means of surgical implantation of the Ankle Spacer prosthesis in an open manner replacing the talar side of the tibiotalar joint.
Study: NCT04203602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: telepresence discharge
Description: Patients will be seen during ward rounds by the multidisciplinary team physically present, but with the surgeon remotely present via a telepresence robot.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional discharge
Description: Patients will be seen during ward rounds by the whole multidisciplinary team physically present, including the surgeon.
Study: NCT02291666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRCHUM-MT cocktail

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRCHUM-MT cocktail

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRCHUM-MT cocktail
Study: NCT00894608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole + gonadotropins
Description: patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa + gonadotropins
Description: patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
Study: NCT02483221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone is given intravenously by TCI-PCA. The TCI-PCA system steer the hydromorphone infusion pump to achieve plasma and effect-site concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma and effect-site concentration range, lockout times and infusion speed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine is given intravenously by PCA. The PCA pump administers a predefined bolus dose on patient request considering the predefined lockout time and infusion speed.
Study: NCT01308021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: entero-coated capsules containing 400µg of gpASIT+TM, daily , 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: entero-coated capsules containing 800 µg of gpASIT+TM, daily, 28 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo entero-coated capsules
Study: NCT03545685

Intervention type: OTHER
Group type: OTHER
Intervention: specific memory and attention realtime training
Description: The investigator will conduct a pilot study of 80 APS subjects (age 18-45). The investigator will examine SMART feasibility and user engagement using a randomized control trial research design. Using a simple random method, 40 APS subjects will be randomly assigned to the experimental group to receive add-on SMART intervention for 3 months and 40 APS subjects will just get naturalistic treatment with no SMART intervention. At baseline and 3-month follow-up, subjects will complete questionnaires on app use habits and attitudes towards SMART feasibility and engagement. In-depth interviews will be conducted at both time points to cross-validate the findings obtained from the questionnaires.
Study: NCT01857531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Pre-Quit Period:~Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.~Post-Quit Period:~Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Pre-Quit Period:~Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.~Post-Quit Period:~Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week).
Study: NCT04304144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAEL-101
Description: The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAEL-101
Description: The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)
Description: According to institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)
Description: According to institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Treatment for AL amyloidosis
Study: NCT00827450

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ctl
Description: Control, isocaloric diet; no coffee

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High fructose diet; no coffee
Description: Hypercaloric, high fructose diet; no coffee

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fully torrefied, caffeine-free coffee
Description: Hypercaloric, high fructose diet + coffee

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: partially torrefied, caffeine-free coffee
Description: Hypercaloric, high fructose diet + coffee

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially torrefied, caffeinated coffee
Description: Hypercaloric, high fructose diet + coffee
Study: NCT04271956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Cycle (q21d): Day 1: Tislelizumab i.v. 200 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Cycle (q21d): Day 1: Tislelizumab i.v. 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Cycle 1: Sonrotoclax Start Ramp-up to 320 mg QD po Days 1-2 Sonrotoclax 2 mg (2 tabl. at 1mg) Days 3-4 Sonrotoclax 5 mg (1 tabl. at 5mg) Days 5-6 Sonrotoclax 10 mg (2 tabl. at 5mg) Days 7-8 Sonrotoclax 20 mg (1 tabl. at 20mg) Days 9-10 Sonrotoclax 40 mg (2 tabl. at 20mg) Days 11-12 Sonrotoclax 80 mg (1 tabl. at 80mg) Days 13-14 Sonrotoclax 160 mg (2 tabl. at 80mg) Days 15-16 Sonrotoclax 320 mg (4 tabl. at 80mg)~Cycle 2-6: Day 1-21 Sonrotoclax 320 mg QD po
Study: NCT03759132

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different chronic neurological conditions, including Parkinson's disease.
Study: NCT03545685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific memory and attention realtime training
Description: The investigator will conduct a pilot study of 80 APS subjects (age 18-45). The investigator will examine SMART feasibility and user engagement using a randomized control trial research design. Using a simple random method, 40 APS subjects will be randomly assigned to the experimental group to receive add-on SMART intervention for 3 months and 40 APS subjects will just get naturalistic treatment with no SMART intervention. At baseline and 3-month follow-up, subjects will complete questionnaires on app use habits and attitudes towards SMART feasibility and engagement. In-depth interviews will be conducted at both time points to cross-validate the findings obtained from the questionnaires.
Study: NCT02313168

Intervention type: OTHER
Intervention: observation, inspection

Intervention type: OTHER
Intervention: observation, inspection
Study: NCT04091789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pure Femme Tablets
Description: A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene and peppermint oil.
Study: NCT03324620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific program functional and respiratory rehabilitation
Description: It is a question of introducing a small program of physical activation pre-transplantation of hematopoietic progenitors, to continue developing it during the hospitalization and to use the functional measurements as a measure of its impact, as well as the different quality of life questionnaires.
Study: NCT04957251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior approach to the hip
Description: anterior hip hemiarthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior approach to the hip
Description: posterior hip hemiarthroplasty
Study: NCT00464958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual tizanidine 12 mg
Description: Single sublingual tizanidine 12 mg tablet, to be administered once nightly, via sublingual administration for 12 months
Study: NCT02737254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 40 IU/ML nasal spray. One administration: children \<40kg administer 12IU, children \>40kg administer 24IU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU/ML nasal spray. One administration: children \<40kg administer 12IU, children \>40kg administer 24IU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0,9 % nasal spray.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: NaCl 0,9 % nasal spray.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secure CBM training
Description: Children are trained to interpret ambiguous maternal behavior in a secure way.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Secure CBM training
Description: Children are trained to interpret ambiguous maternal behavior in a secure way.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral CBM training
Description: Children receive a training unrelated to the interpretation of maternal behavior.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neutral CBM training
Description: Children receive a training unrelated to the interpretation of maternal behavior.
Study: NCT04573049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min levosimendan is given for 24 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min 5% glucose infusion is given for 24 hours.
Study: NCT03316651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months.
Study: NCT00780130

Intervention type: OTHER
Intervention: No Intervention
Description: male \& female college students ages 20 to 50, asymptomatic normals
Study: NCT03033368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Rilpivirine 25 mg tablet
Study: NCT00838656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV in one of two schedules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV in one of two schedules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV in one of two schedules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV in one of two schedules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV in one of two schedules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV in one of two schedules
Study: NCT03719781

Intervention type: DIAGNOSTIC_TEST
Intervention: standardized minimental testing
Description: To diagnose postoperative cognitive dysfunction
Study: NCT03252977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored regimen of IV PCA according to pain sensitivity
Description: In tailored group, fentanyl dosage in IV PCA will be determined according to preoperative pain sensitivity. In control, group, fentanyl dosage in IV PCA will be determined without consideration of patient's pain sensitivity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Regimen of IV PCA without considering pain sensitivity
Description: In control group, regimen of IV PCA will be determined without consideration about patient's pain sensitivity.
Study: NCT01962012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcceleDent Aura

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Study: NCT00424619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: 50 000 IU vitamin D2, one time bolus dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: 100 000 IU vitamin D2, one time bolus dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 time bolus dose
Study: NCT02549859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) at 60 Hz
Description: Bilateral subthalamic nucleus deep brain stimulation at 60 Hz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) at 130 Hz
Description: Bilateral subthalamic nucleus deep brain stimulation at 130 Hz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) Off (Sham)
Description: Deep Brain Stimulation (DBS) Off (Sham)
Study: NCT03616574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA102N
Description: CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA102N
Description: CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA102N
Description: CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LONSURF
Description: LONSURF is a cytotoxic combination treatment of 2 new drugs: trifluridine, a thymidine-based nucleoside analog, and tipiracil, an inhibitor of thymidine phosphorylase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LONSURF
Description: LONSURF is a cytotoxic combination treatment of 2 new drugs: trifluridine, a thymidine-based nucleoside analog, and tipiracil, an inhibitor of thymidine phosphorylase.
Study: NCT02790567

Intervention type: OTHER
Intervention: HEP score
Description: The HEP score is a clinicobiological score evaluating the probability of the HIT diagnosis.~The HEP score is based on the blood platelet count, the timing of the platelet decrease, the existence of clinical manifestations of HIT (thrombosis, haemorrhage, skin necrosis) and the existence of an other cause of thrombocytopenia.

Intervention type: OTHER
Intervention: 4Ts score
Description: The 4Ts score is a clinicobiological score evaluating the probability of the HIT diagnosis. The 4Ts score is based on the change in blood platelet count during heparin therapy, the timing of platelet decrease, the existence of a thrombosis, and the existence of an other cause of thrombocytopenia.

Intervention type: OTHER
Intervention: ID-PaGIA test
Description: The ID-PaGIA test is a particle gel immunoassay that detects immunoglobulins (Ig) G, A and M specific to the heparin/PF4 complexes.

Intervention type: OTHER
Intervention: HIT-Ab(PF4-H) test
Description: The HIT-Ab(PF4-H) test consist in the incubation of plasma samples with latex beads coated PF4/polyvinylsulfate complexes. After binding of the plasma antibodies a monoclonal antibody recognizing PF4/heparin complexes is added. In the presence of human anti-PF4/heparin antibodies, binding of the monoclonal antibody and subsequent agglutination of latex beads is inhibited. Inhibition of agglutination is quantified and reported in arbitrary units (U/ml). A value equal or higher than 1.0 u/ml may indicate the presence of HIT antibodies.
Study: NCT05082675

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HLA Matched allogeneic transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HLA Matched allogeneic transplant
Study: NCT03207048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 3-second trains with a 15-second inter-train interval, for 50 trains per session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: Sham Transcranial Magnetic Stimulation
Study: NCT03240068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7
Description: This is a biologically active hormone of the renin-angiotensin system. It may play a beneficial role in regulation of blood pressure by dilating blood vessels and reducing inflammation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline will be used as the placebo comparator.